{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T07:20:22Z","timestamp":1773040822561,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2010,4,20]],"date-time":"2010-04-20T00:00:00Z","timestamp":1271721600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.1007\/s00228-010-0820-7","type":"journal-article","created":{"date-parts":[[2010,4,19]],"date-time":"2010-04-19T09:00:34Z","timestamp":1271667634000},"page":"791-795","source":"Crossref","is-referenced-by-count":15,"title":["Fluconazole-induced intoxication with phenytoin in a patient with ultra-high activity of CYP2C9"],"prefix":"10.1007","volume":"66","author":[{"given":"Anders","family":"Helld\u00e9n","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulf","family":"Bergman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karin","family":"Engstr\u00f6m Hellgren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mich\u00e8le","family":"Masquelier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingela","family":"Nilsson Remahl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingegerd","family":"Odar-Cederl\u00f6f","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margareta","family":"Ramsj\u00f6","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leif","family":"Bertilsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,4,20]]},"reference":[{"key":"820_CR1","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1097\/00007691-198512000-00021","volume":"7","author":"L Bertilsson","year":"1985","unstructured":"Bertilsson L, Aberg-Wistedt A, Gustafsson LL, Nordin C (1985) Extremely rapid hydroxylation of debrisoquine: a case report with implication for treatment with nortriptyline and other tricyclic antidepressants. Ther Drug Monit 7:478\u2013480","journal-title":"Ther Drug Monit"},{"key":"820_CR2","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/0140-6736(93)92546-6","volume":"341","author":"L Bertilsson","year":"1993","unstructured":"Bertilsson L, Dahl ML, Sj\u00f6qvist F, Aberg-Wistedt A, Humble M, Johansson I, Lundqvist E, Ingelman-Sundberg M (1993) Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine. Lancet 341:63","journal-title":"Lancet"},{"key":"820_CR3","doi-asserted-by":"crossref","first-page":"11825","DOI":"10.1073\/pnas.90.24.11825","volume":"90","author":"I Johansson","year":"1993","unstructured":"Johansson I, Lundqvist E, Bertilsson L, Dahl ML, Sj\u00f6qvist F, Ingelman-Sundberg M (1993) Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci USA 90:11825\u201311829","journal-title":"Proc Natl Acad Sci USA"},{"key":"820_CR4","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00228-003-0701-4","volume":"59","author":"C Kawanishi","year":"2004","unstructured":"Kawanishi C, Lundgren S, Agren H, Bertilsson L (2004) Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse. A pilot study. Eur J Clin Pharmacol 59:803\u2013807","journal-title":"Eur J Clin Pharmacol"},{"key":"820_CR5","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1046\/j.0306-5251.2001.01548.x","volume":"53","author":"L Bertilsson","year":"2002","unstructured":"Bertilsson L, Dahl ML, Dal\u00e9n P, Al-Shurbaji A (2002) Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol 53:111\u2013122","journal-title":"Br J Clin Pharmacol"},{"key":"820_CR6","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.clpt.2005.10.002","volume":"79","author":"SC Sim","year":"2006","unstructured":"Sim SC, Risinger C, Dahl ML, Aklillu E, Christensen M, Bertilsson L, Ingelman-Sundberg M (2006) A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther 79:103\u2013113","journal-title":"Clin Pharmacol Ther"},{"key":"820_CR7","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1007\/s00228-008-0529-z","volume":"64","author":"S Ohlsson Rosenborg","year":"2008","unstructured":"Ohlsson Rosenborg S, Mwinyi J, Andersson M, Baldwin R, Pedersen R, Sim S, Bertilsson L, Ingelman-Sundberg M, Eliasson E (2008) Kinetics of omeprazole and escitalopram in relation to the CYP2C19*17 allele in healthy subjects. Eur J Clin Pharmacol 64:1175\u20131179","journal-title":"Eur J Clin Pharmacol"},{"key":"820_CR8","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0140-6736(98)04474-2","volume":"353","author":"GP Aithal","year":"1999","unstructured":"Aithal GP, Day CP, Kesteven PJ, Daly AK (1999) Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 353:717\u2013719","journal-title":"Lancet"},{"key":"820_CR9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clpt.2004.08.009","volume":"77","author":"J Kirchheiner","year":"2005","unstructured":"Kirchheiner J, Brockm\u00f6ller J (2005) Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin Pharmacol Ther 77:1\u201316","journal-title":"Clin Pharmacol Ther"},{"key":"820_CR10","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1528-1167.2008.01561.x","volume":"49","author":"PN Patsalos","year":"2008","unstructured":"Patsalos PN, Berry DJ, Bourgeois BF, Cloyd JC, Glauser TA, Johannessen SI, Leppik IE, Tomson T, Perucca E (2008) Antiepileptic drugs\u2014best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia 49:1239\u20131276","journal-title":"Epilepsia"},{"key":"820_CR11","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0009-9236(03)00050-X","volume":"73","author":"M Christensen","year":"2003","unstructured":"Christensen M, Andersson K, Dal\u00e9n P, Mirghani RA, Muirhead GJ, Nordmark A, Tybring G, Wahlberg A, Yasar U, Bertilsson L (2003) The Karolinska cocktail for phenotyping of five human cytochrome P450 enzymes. Clin Pharmacol Ther 73:517\u2013528","journal-title":"Clin Pharmacol Ther"},{"key":"820_CR12","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1046\/j.1365-2125.2002.01646.x","volume":"54","author":"U Yasar","year":"2002","unstructured":"Yasar U, Dahl ML, Christensen M, Eliasson E (2002) Intra-individual variability in urinary losartan oxidation ratio, an in vivo marker of CYP2C9 activity. Br J Clin Pharmacol 54:183\u2013185","journal-title":"Br J Clin Pharmacol"},{"key":"820_CR13","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/0009-9236(95)90053-5","volume":"58","author":"SM Morais de","year":"1995","unstructured":"de Morais SM, Goldstein JA, Xie HG, Huang SL, Lu YQ, Xia H, Xiao ZS, Ile N, Zhou HH (1995) Genetic analysis of the S-mephenytoin polymorphism in a Chinese population. Clin Pharmacol Ther 58:404\u2013411","journal-title":"Clin Pharmacol Ther"},{"key":"820_CR14","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s00228-008-0612-5","volume":"65","author":"Y B\u00f6ttiger","year":"2009","unstructured":"B\u00f6ttiger Y, Laine K, Andersson ML, Korhonen T, Molin B, Ovesj\u00f6 ML, Tirkkonen T, Rane A, Gustafsson LL, Eiermann B (2009) SFINX-a drug-drug interaction database designed for clinical decision support systems. Eur J Clin Pharmacol 65:627\u2013633","journal-title":"Eur J Clin Pharmacol"},{"key":"820_CR15","unstructured":"Flockhart D (2007) Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine. Available at: http:\/\/medicine.iupui.edu\/clinpharm\/ddis\/table.asp . Accessed 15 Feb 2010"},{"key":"820_CR16","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/j.1365-2125.2008.03104.x","volume":"65","author":"RM Baldwin","year":"2008","unstructured":"Baldwin RM, Ohlsson S, Pedersen RS, Mwinyi J, Ingelman-Sundberg M, Eliasson E, Bertilsson L (2008) Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers. Br J Clin Pharmacol 65:767\u2013774","journal-title":"Br J Clin Pharmacol"},{"key":"820_CR17","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/clpt.2008.132","volume":"84","author":"KP Kanebratt","year":"2008","unstructured":"Kanebratt KP, Diczfalusy U, B\u00e4ckstr\u00f6m T, Sparve E, Bredberg E, B\u00f6ttiger Y, Andersson TB, Bertilsson L (2008) Cytochrome P450 induction by rifampicin in healthy subjects: determination using the Karolinska cocktail and the endogenous CYP3A4 marker 4beta-hydroxycholesterol. Clin Pharmacol Ther 84:589\u2013594","journal-title":"Clin Pharmacol Ther"},{"key":"820_CR18","doi-asserted-by":"crossref","first-page":"38685","DOI":"10.1074\/jbc.M105127200","volume":"276","author":"K Bodin","year":"2001","unstructured":"Bodin K, Bretillon L, Aden Y, Bertilsson L, Broom\u00e9 U, Einarsson C, Diczfalusy U (2001) Antiepileptic drugs increase plasma levels of 4beta-hydroxycholesterol in humans: evidence for involvement of cytochrome P450 3A4. J Biol Chem 276:38685\u201338689","journal-title":"J Biol Chem"},{"key":"820_CR19","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/jbt.20264","volume":"23","author":"J Sahi","year":"2009","unstructured":"Sahi J, Shord SS, Lindley C, Ferguson S, LeCluyse EL (2009) Regulation of cytochrome P450 2C9 expression in primary cultures of human hepatocytes. J Biochem Mol Toxicol 23:43\u201358","journal-title":"J Biochem Mol Toxicol"},{"key":"820_CR20","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jaut.2009.02.011","volume":"32","author":"D Mendes","year":"2009","unstructured":"Mendes D, Correia M, Barbedo M, Vaio T, Mota M, Gon\u00e7alves O, Valente J (2009) Beh\u00e7et's disease\u2014a contemporary review. J Autoimmun 32:178\u2013188","journal-title":"J Autoimmun"},{"key":"820_CR21","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/clpt.2008.302","volume":"85","author":"ET Morgan","year":"2009","unstructured":"Morgan ET (2009) Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics. Clin Pharmacol Ther 85:434\u2013438","journal-title":"Clin Pharmacol Ther"},{"key":"820_CR22","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1093\/clinchem\/33.9.1679","volume":"33","author":"K Chaleby","year":"1987","unstructured":"Chaleby K, el-Yazigi A, Atiyeh M (1987) Decreased drug absorption in a patient with Beh\u00e7et\u2019s syndrome. Clin Chem 33:1679\u20131681","journal-title":"Clin Chem"},{"key":"820_CR23","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1365-4632.2007.02957.x","volume":"46","author":"U Tursen","year":"2007","unstructured":"Tursen U, Tamer L, Api H, Yildirim H, Baz K, Ikizoglu G, Atik U (2007) Cytochrome P450 polymorphisms in patients with Beh\u00e7et's disease. Int J Dermatol 46:153\u2013156","journal-title":"Int J Dermatol"},{"key":"820_CR24","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S0735-1097(84)80304-6","volume":"3","author":"S Ahmad","year":"1984","unstructured":"Ahmad S (1984) Nifedipine\u2013phenytoin interaction. J Am Coll Cardiol 3:1582","journal-title":"J Am Coll Cardiol"},{"key":"820_CR25","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1002\/j.1552-4604.1988.tb03139.x","volume":"28","author":"GT Blyden","year":"1988","unstructured":"Blyden GT, Scavone JM, Greenblatt DJ (1988) Metronidazole impairs clearance of phenytoin but not of alprazolam or lorazepam. J Clin Pharmacol 28:240\u2013245","journal-title":"J Clin Pharmacol"},{"key":"820_CR26","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1097\/00004714-199910000-00013","volume":"19","author":"MU Shad","year":"1999","unstructured":"Shad MU, Preskorn SH (1999) Drug-drug interaction in reverse: possible loss of phenytoin efficacy as a result of fluoxetine discontinuation. J Clin Psychopharmacol 19:471\u2013472","journal-title":"J Clin Psychopharmacol"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-010-0820-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-010-0820-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-010-0820-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,3]],"date-time":"2020-06-03T21:17:41Z","timestamp":1591219061000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-010-0820-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4,20]]},"references-count":26,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["820"],"URL":"https:\/\/doi.org\/10.1007\/s00228-010-0820-7","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,4,20]]}}}